BlackRock Health Sciences Opps R holds a quantitatively derived Bronze Morningstar Medalist Rating. The rating reflects that it has scored better than the norm on factors Morningstar research associates with future outperformance relative to category peers.
BlackRock Health Sciences Opportunities Portfolio Class R BHSRX
- NAV / 1-Day Return 60.50 / −0.54 %
- Total Assets 5.9B
-
Adj. Expense Ratio
1.440%
- Expense Ratio 1.440%
- Distribution Fee Level Above Average
- Share Class Type Retirement, Medium
- Category Health
- Investment Style Large Value
- Min. Initial Investment 100
- Status Open
- TTM Yield 0.10%
- Turnover 43%
USD | NAV as of Jun 18, 2026 | 1-Day Return as of Jun 18, 2026, 12:58 AM GMT+0
Morningstar’s Analysis BHSRX
Will BHSRX outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
The People Pillar is our evaluation of the BHSRX management team’s experience and ability. We find that high-quality management teams deliver superior performance relative to their benchmarks and/or peers.
Parent Pillar
The Parent Pillar is our rating of BHSRX’s parent organization’s priorities and whether they’re in line with investors’ interests.
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 50.7
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Eli Lilly and Co | 10.79 | 631M | Healthcare |
Johnson & Johnson | 9.51 | 556M | Healthcare |
UnitedHealth Group Inc | 6.00 | 351M | Healthcare |
Merck & Co Inc | 4.34 | 254M | Healthcare |
AbbVie Inc | 4.18 | 245M | Healthcare |
Gilead Sciences Inc | 3.89 | 227M | Healthcare |
Amgen Inc | 3.48 | 204M | Healthcare |
Thermo Fisher Scientific Inc | 2.97 | 174M | Healthcare |
Intuitive Surgical Inc | 2.84 | 166M | Healthcare |
Pfizer Inc | 2.69 | 158M | Healthcare |
United States